Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer | Zendy

Emil Lou | Zendy; Rachel I. Vogel | Zendy; Deanna Teoh | Zendy; Spencer Hoostal | Zendy; A. Grad | Zendy; Matthew S. Gerber | Zendy; Minnu Monu | Zendy; Tomasz Łukaszewski | Zendy; Jaai Deshpande | Zendy; Michael A. Linden | Zendy; Melissa A. Geller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer

Author(s) -

Emil Lou,

Rachel I. Vogel,

Deanna Teoh,

Spencer Hoostal,

A. Grad,

Matthew S. Gerber,

Minnu Monu,

Tomasz Łukaszewski,

Jaai Deshpande,

Michael A. Linden,

Melissa A. Geller

Publication year - 2017

Publication title -

laboratory medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.332

H-Index - 28

eISSN - 1943-7730

pISSN - 0007-5027

DOI - 10.1093/labmed/lmx084

Subject(s) - medicine , ovarian cancer , biomarker , circulating tumor cell , oncology , prostate cancer , stage (stratigraphy) , colorectal cancer , cancer , prospective cohort study , ovarian carcinoma , pathology , metastasis , paleontology , biochemistry , chemistry , biology

The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical study was to determine whether pretreatment CTCs are a useful diagnostic biomarker in women with complex pelvic masses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research